Twist Bioscience Corp (TWST) stock
Close on Nov 11, 2026Market cap $7.69BP/E –Yield –
Twist Bioscience Corp grew revenue 19.2% to $431.80M over the twelve months to Jun 30, 2026. Free cash flow was -$93.12M. At the latest close the market valued the company at $7.69B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.69B
- P/E ratio
- –
- Price to sales
- 17.80
- Price to book
- 17.25
- Dividend yield
- –
- Free cash flow yield
- -1.21%
Fundamentals
- Revenue
- $431.80M
- Net income
- -$136.72M
- EPS, diluted
- -$2.22
- Free cash flow
- -$93.12M
- Book value per share
- $7.14
- Diluted shares
- 62M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $132.13
- Open
- $140.98
- Day's range
- $122.08 – $151.50
- Volume
- 3,479,921
- Average volume (20 days)
- 2,380,844
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 2.29
- 52-week range
- $23.30 – $219.71
- RSI (14 days)
- 41.4
- Volatility (1 year)
- 83.9%
- Relative volume
- 1.65×
- WACC
- 16.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TWST | S&P 500 | Difference | TWST per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.3% | -2.4% | −20.9 pts | ||
| 3 months | -0.4% | -1.2% | +0.7 pts | ||
| Year to date | +286.5% | +12.3% | +274.2 pts | ||
| 1 year | +291.4% | +12.4% | +279.0 pts | ||
| 3 years | +626.7% | +78.8% | +547.9 pts | +93.7% | +21.4% |
| 5 years | +5.4% | +75.2% | −69.8 pts | +1.1% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Twist Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
About Twist Bioscience
Biological Products, (No Diagnostic Substances)
Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA using a proprietary silicon chip platform. Its primary offerings comprise synthetic biology tools—such as clonal genes, gene fragments, oligo pools, and IgG proteins—and next-generation sequencing products, including target enrichment panels and library preparation kits. In addition, the company provides biopharma solutions for antibody discovery, optimization, and characterization. It sells products and services to biopharmaceutical companies, diagnostic laboratories, agricultural enterprises, chemical manufacturers, and academic research institutions.
Company profile, executives and historyTwist Bioscience stock: common questions
What is Twist Bioscience's stock price?
TWST closed at $122.59 on Nov 11, 2026, down 7.22% on the day. Over the past 52 weeks it traded between $23.30 and $219.71.
What is Twist Bioscience's market cap?
Twist Bioscience was worth $7.69B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TWST's P/E ratio?
Twist Bioscience lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.22), so it has no meaningful P/E ratio.
How much revenue does Twist Bioscience make?
Twist Bioscience reported revenue of $431.80M for the twelve months to Jun 30, 2026, up 19.2% from a year earlier.
Does Twist Bioscience pay a dividend?
No. Twist Bioscience has not paid a cash dividend over the last twelve months.
When does Twist Bioscience report earnings next?
Twist Bioscience is expected to report Q4 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TWST stock performed over the past year?
Including dividends, TWST returned +291.4% over the past year, against +12.4% for the S&P 500.
How many TWST shares are sold short?
10M shares were sold short at the latest FINRA report, 16.03% of the float, or 4.3 days of average trading volume.
Who are Twist Bioscience's competitors?
Companies most similar to Twist Bioscience by business, industry and size include TECH, MGTX, RGEN, KRYS, IMCR.
See a number that looks wrong?